RATING SCHEDULE · DC 6014

Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) · DC 6014

Compare the 6 rating levels listed for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) under DC 6014 and see which findings distinguish them.

This entry covers evaluation under DC 6014. A clinician establishes the diagnosis separately.

How is it connected to service?

The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.

Explore service-connection evidence →

What do the rating levels describe?

A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.

0%

The source describes this level as:

  • The requirements for a compensable evaluation are not met. A 0% evaluation may apply under §4.31.

10%

The source describes this level as:

  • With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months

20%

The source describes this level as:

  • With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months

40%

The source describes this level as:

  • With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months

60%

The source describes this level as:

  • With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months

100%

The source describes this level as:

  • Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation
Compare these levels with the original rating table

Find DC 6014 in the rating schedule

The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.

38 CFR Part 4 · excerpt surrounding DC 6014
Rating
6013 Open-angle glaucoma
Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required10
6014 Malignant neoplasms of the eye, orbit, and adnexa (excluding skin):
Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation100
Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals
Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that do not require therapy comparable to that for systemic malignancies:
Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations
6015 Benign neoplasms of the eye, orbit, and adnexa (excluding skin):
Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations

What an examination for visual impairment measures

When this code calls for evaluation of visual impairment, distinguish visual acuity, field loss and eye-muscle function in the examination report. The applicable findings depend on the condition.

Read 38 CFR §4.75 ↗
Related notes and evaluation rules

Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals

Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091

Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes

Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions

Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals |

Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations |

Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation |

Official rating schedule · DC 6014, §4.79 ↗

Which evidence addresses the questions?

  • The documented diagnosis and applicable diagnostic code.
  • Clinical findings and functional effects addressing the applicable source criteria.
  • Timing, treatment and connection-to-service evidence for the applicable claim route.
How an independent medical review works →

Sources and scope

Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.

Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.

About these educational tools

The calculator and guides provide general education, not medical, legal, or financial advice. Using them does not create a clinician-patient, evaluator-evaluee, or attorney-client relationship. Professional services require a separate accepted engagement.

VA determines eligibility, service connection, ratings, qualifying dependents, effective dates, and the amount payable. Using these tools does not submit a claim or appeal.

Diagnosis, connection to service, and severity are separate questions. Matching a description or screening score does not establish a diagnosis or entitlement. A qualified clinician should interpret medical findings. Do not change treatment based on these guides.

Ingleside Health is an independent physician service, not a law firm or VA-accredited claims representative. It is not affiliated with or endorsed by VA and does not prepare, present, prosecute, or file benefits claims.

Do not rely on an estimate alone for financial commitments or claim decisions. Check official VA information and seek appropriate individual advice.

Calculation assumptions and exclusions
  • Basic compensation estimate. Special Monthly Compensation (SMC), Total Disability based on Individual Unemployability (TDIU), offsets or recoupment, back pay, temporary total ratings, and unsupported adult-dependent categories are not calculated.
  • Bilateral handling covers the supported arm/leg selections. Other paired skeletal muscles, amputation limits, and overlapping manifestations need individual review. The tool cannot determine whether every entered rating may be separately combined.
  • Use separately established evaluations or clearly hypothetical percentages. Choosing a condition or percentage does not establish diagnosis, service connection, or entitlement.
  • Uses 2026 compensation rates effective December 1, 2025. Historical payments, future rate changes, and individual effective dates are not calculated. See the source dates on each reference; rules and rates may change.
Using the website or a chat tool

Calculator selections stay in this browser tab's memory and are not saved or submitted as intake. Refreshing the page resets the example. Do not enter personal records or identifiers. Website visits remain subject to the Website Privacy Policy.

Use hypothetical scenarios only in chat tools. Do not send records, identifiers, symptoms, or real case information. The chat provider's own terms and privacy settings apply; a chat conversation is not the Box-hosted clinical intake.

Accredited Veterans Service Organization (VSO) representatives provide free help with VA benefit claims. Find VA-accredited help. Read VA’s official rating guidance.

Terms of UseWebsite Privacy PolicyAccessibility and help

This business is not endorsed or sponsored by, or affiliated with, the United States Department of Veterans Affairs or the Illinois Department of Veterans Affairs, or any federally chartered VA accredited veteran service organization. You may qualify for other veterans benefits beyond the benefits for which you are receiving services here.

Veteran and military benefits services are available free of charge from VA accredited county veteran service officers, representatives of the Illinois Department of Veterans Affairs, and the veteran service officers of federally chartered veteran service organizations. To learn more, contact these organizations or the Illinois Attorney General's Office at 1-800-382-3000.